Evidence map›Paper›PMID 37809920›Full record

ReviewHeliyon2023

The interplay between monosodium glutamate (MSG) consumption and metabolic disorders.

Omowumi T Kayode, Jemilat A Bello, Jamiu A Oguntola, Abolanle A A Kayode, Daniel K Olukoya

RetractedOpen access · goldAbstract readReviewRetracted Publication
In one paragraph

Review in Heliyon, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It has been retracted, and should not be counted. Cited by 24 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
24citing papers in PubMed, 1 pooled it
8.1field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

24 citing papers in PubMed, 1 synthesis or guideline pooled it, 50 citations in OpenAlex.

  1. Pooled it
  2. Experimental models in diabetes research.Laboratory animal research · 2026
    Review
  3. Monosodium glutamate-mediated CaPhysiological reports · 2026
    Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Review
  9. Article
  10. Article
  11. Article
  12. Article
  13. Review
  14. Article
  15. Article
  16. Observational
  17. Article
  18. Rutin andFrontiers in veterinary science · 2025
    Article
  19. Ethnomedicinal validation ofFrontiers in nutrition · 2025
    Article
  20. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

5 authors at 3 institutions in 1 country.

Omowumi T KayodeDepartment of Biochemistry, College of Basic and Applied Sciences, Mountain Top University, Prayer City, Nigeria.
Jemilat A BelloDepartment of Biochemistry, College of Basic and Applied Sciences, Mountain Top University, Prayer City, Nigeria.
Jamiu A OguntolaDepartment of Biochemistry, College of Basic and Applied Sciences, Mountain Top University, Prayer City, Nigeria.
Abolanle A A KayodeDepartment of Biochemistry, School of Basic Medical Sciences, Babcock University, Ilishan-Remo, Nigeria.
Daniel K OlukoyaDepartment of Biological Sciences, College of Basic and Applied Sciences, Mountain Top University, Prayer City, Nigeria.
Lagos State University · NGMountain Top University · NGBabcock University · NG

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Monosodium glutamate (MSG) is one of the most popular food additives in the world and is often ingested with commercially processed foods. It can be described as a sodium salt of glutamic acid with the IUPAC name - Sodium 2-aminopentanedioate and is ionized by water to produce free sodium ions and glutamic acid. MSG use has significantly increased over the past 30 years, its global demand stands huge at over three million metric tons which is worth over $4.5 billion. Asia was responsible for more than three quarter of world MSG consumption with the country China also leading in global consumption as well as production and export to other countries. Prior to year 2020, global demand for MSG increased by almost four percent each year with the highest significant increase in demand for MSG predicted to rise in Thailand, Indonesia, Vietnam and China, followed by Brazil and Nigeria. However, several researches featured in this review has identified MSG consumption as a major contributor to the development and progression of some metabolic disorders such as obesity, which is a risk factor for other metabolic syndromes like hypertension, diabetes mellitus and cancer initiation. The mechanism by which MSG induce obesity involves induction of hypothalamic lesion, hyperlipidemia, oxidative stress, leptin resistance and increased expression of peroxisome proliferator-activated receptors (PPARs) Gamma and Alpha. Similarly for induction of diabetes mellitus, MSG consumption resulted in decreased pancreatic beta cell mass, increased oxidative stress and metabolic rates, reduced glucose and insulin transport to adipose tissue and skeletal muscles, insulin insensitivity, reduced insulin receptors and induced severe hyperinsulinemia. Dietary salt, an active component of MSG is also found to be a major risk factor for high blood pressure (which may lead to hypertension). MSG is used to enhance the taste of tobacco, causing smokers to consume the product in excess and thereby increasing the risk of cancer development. Depending on the amount consumed, MSG has both positive and negative effects. Despite the controversy surrounding MSG's safety and its probable contribution to risk of development and progression of metabolic disorders, its global consumption is still very high. Therefore, this article will sensitize the public on the need for cautious use of MSG in foods and also aid regulatory agencies to further review the daily MSG consumption limit based on metabolic toxicities observed at the varied dosages reported in this review.

Indexed as

Diabetes mellitusHypertensionMetabolic disordersMonosodium glutamateObesity

Identifiers

PMID37809920
PMCPMC10558944
OpenAlexW4386572213

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.